DE60218327D1 - Inaktivierte immunogene bakterielle ganzzell-zusammensetzungen - Google Patents
Inaktivierte immunogene bakterielle ganzzell-zusammensetzungenInfo
- Publication number
- DE60218327D1 DE60218327D1 DE60218327T DE60218327T DE60218327D1 DE 60218327 D1 DE60218327 D1 DE 60218327D1 DE 60218327 T DE60218327 T DE 60218327T DE 60218327 T DE60218327 T DE 60218327T DE 60218327 D1 DE60218327 D1 DE 60218327D1
- Authority
- DE
- Germany
- Prior art keywords
- incapacitated
- bacterial
- bacterium
- lys minus
- replication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001580 bacterial effect Effects 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000894006 Bacteria Species 0.000 abstract 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 230000010076 replication Effects 0.000 abstract 2
- 241001515965 unidentified phage Species 0.000 abstract 2
- 101710126949 Lysin Proteins 0.000 abstract 1
- 229960001212 bacterial vaccine Drugs 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32579601P | 2001-09-27 | 2001-09-27 | |
| US325796P | 2001-09-27 | ||
| PCT/US2002/030844 WO2003026690A1 (en) | 2001-09-27 | 2002-09-27 | Incapacitated whole-cell immunogenic bacterial compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60218327D1 true DE60218327D1 (de) | 2007-04-05 |
| DE60218327T2 DE60218327T2 (de) | 2007-10-31 |
Family
ID=23269486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60218327T Expired - Lifetime DE60218327T2 (de) | 2001-09-27 | 2002-09-27 | Inaktivierte immunogene bakterielle ganzzell-zusammensetzungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6913753B2 (de) |
| EP (1) | EP1438066B1 (de) |
| JP (2) | JP4554206B2 (de) |
| AT (1) | ATE354370T1 (de) |
| CA (1) | CA2461710C (de) |
| DE (1) | DE60218327T2 (de) |
| ES (1) | ES2282460T3 (de) |
| MX (1) | MXPA04002866A (de) |
| WO (1) | WO2003026690A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020192676A1 (en) * | 2001-06-18 | 2002-12-19 | Madonna Angelo J. | Method for determining if a type of bacteria is present in a mixture |
| JP4849772B2 (ja) * | 2001-09-27 | 2012-01-11 | ガンガゲン インコーポレーティッド | 免疫原性が低いリシン欠損バクテリオファージ |
| ES2346424T3 (es) * | 2002-04-12 | 2010-10-15 | Colorado School Of Mines | Procedimiento de deteccion de bajas concentraciones de una bacteria diana que utiliza fagos para infectar celulas bacterianas diana. |
| US20050129711A1 (en) | 2002-11-14 | 2005-06-16 | Janakiraman Ramachandran | Incapacitated whole-cell immunogenic bacterial compositions produced by recombinant expression |
| US8092990B2 (en) * | 2005-03-31 | 2012-01-10 | Colorado School Of Mines | Apparatus and method for detecting microscopic organisms using bacteriophage |
| US20110097702A1 (en) * | 2005-03-31 | 2011-04-28 | Voorhees Kent J | Methods and compositions for in situ detection of microorganisms on a surface |
| US9115389B2 (en) * | 2006-06-30 | 2015-08-25 | Rosetta Genomics Ltd. | Method for detecting a target nucleic acid comprising two portions using probes having a first portion complementary to the first portion of the target nucleic acid and a second portion substantially complementary to the second portion of the target nucleic acid |
| AU2008265989B8 (en) * | 2007-06-15 | 2012-01-12 | Microphage Incorporated | Method of detection of microorganisms with enhanced bacteriophage amplification |
| US8697434B2 (en) * | 2008-01-11 | 2014-04-15 | Colorado School Of Mines | Detection of phage amplification by SERS nanoparticles |
| US9441204B2 (en) * | 2008-04-03 | 2016-09-13 | Colorado School Of Mines | Compositions and methods for detecting Yersinia pestis bacteria |
| CA2833176C (en) | 2011-04-12 | 2023-05-16 | C.B. Appaiah | Chimeric antibacterial polypeptides |
| GB201600075D0 (en) * | 2016-01-03 | 2016-02-17 | Glaxosmithkline Biolog Sa | Immunogenci composition |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US6130082A (en) * | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
| GB9726233D0 (en) * | 1997-12-11 | 1998-02-11 | Medeva Europ Ltd | Vaccines containing attenuated bacteria |
| JP4849772B2 (ja) * | 2001-09-27 | 2012-01-11 | ガンガゲン インコーポレーティッド | 免疫原性が低いリシン欠損バクテリオファージ |
-
2002
- 2002-09-27 MX MXPA04002866A patent/MXPA04002866A/es active IP Right Grant
- 2002-09-27 DE DE60218327T patent/DE60218327T2/de not_active Expired - Lifetime
- 2002-09-27 EP EP02763771A patent/EP1438066B1/de not_active Expired - Lifetime
- 2002-09-27 CA CA2461710A patent/CA2461710C/en not_active Expired - Fee Related
- 2002-09-27 WO PCT/US2002/030844 patent/WO2003026690A1/en active IP Right Grant
- 2002-09-27 JP JP2003530325A patent/JP4554206B2/ja not_active Expired - Fee Related
- 2002-09-27 US US10/259,164 patent/US6913753B2/en not_active Expired - Lifetime
- 2002-09-27 AT AT02763771T patent/ATE354370T1/de not_active IP Right Cessation
- 2002-09-27 ES ES02763771T patent/ES2282460T3/es not_active Expired - Lifetime
-
2010
- 2010-04-01 JP JP2010084948A patent/JP2010180227A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE354370T1 (de) | 2007-03-15 |
| JP4554206B2 (ja) | 2010-09-29 |
| JP2010180227A (ja) | 2010-08-19 |
| US6913753B2 (en) | 2005-07-05 |
| WO2003026690A1 (en) | 2003-04-03 |
| US20030152589A1 (en) | 2003-08-14 |
| DE60218327T2 (de) | 2007-10-31 |
| ES2282460T3 (es) | 2007-10-16 |
| CA2461710A1 (en) | 2003-04-03 |
| JP2005508912A (ja) | 2005-04-07 |
| EP1438066A4 (de) | 2005-10-12 |
| MXPA04002866A (es) | 2005-06-06 |
| EP1438066B1 (de) | 2007-02-21 |
| EP1438066A1 (de) | 2004-07-21 |
| WO2003026690A9 (en) | 2004-09-16 |
| CA2461710C (en) | 2013-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60218327D1 (de) | Inaktivierte immunogene bakterielle ganzzell-zusammensetzungen | |
| WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
| ATE489968T1 (de) | Proteosom-liposaccharid-vakzine-adjuvans | |
| NZ291262A (en) | E. coli heat-labile enterotoxin derivatives and their use as oral adjuvants | |
| EP0400958A3 (de) | Lebende Impfstoffe | |
| DE60226911D1 (de) | Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten | |
| HUP0000992A2 (hu) | Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai | |
| WO2003082183A3 (en) | Protein-based streptococcus pneumoniae vaccines | |
| RU2008102654A (ru) | Инактивированные химерные вакцины и связанные с ними способы применения | |
| DE602004028029D1 (en) | Rwendung | |
| SE9003198L (sv) | Fiskvaccin omfattande en virulent, invasiv bakterie | |
| EP1471936A4 (de) | Hiv-vakzine und anwendungsverfahren | |
| WO2002034773A3 (en) | Streptococcal genes | |
| ATE268384T1 (de) | Analog von haemophilus hin47 mit verminderter protease aktivität | |
| DK1154791T3 (da) | Neisseria-vaccinesammensætninger og fremgangsmåder | |
| Tafuku et al. | Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice | |
| NO20013102D0 (no) | Gener, proteiner og deres anvendelse | |
| DE60143810D1 (de) | Vakzine gegen ipnv die aus hefezellen isoliert werden | |
| CY1107560T1 (el) | Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο | |
| SE9903534D0 (sv) | Vaccin | |
| HUP0101081A2 (hu) | Tápközeg és eljárás vírustenyésztésre és szaporításra | |
| TW200509964A (en) | VP1 of foot-and-mouth disease virus | |
| CA1319634C (en) | Vaccine | |
| WO2004050692A3 (en) | Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production | |
| HUP0200162A2 (hu) | Haemophilus somnus transzferrin-kötő fehérjék klónozása és expresszálása |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |